In addition, phase I and II clinical trials have previously examined the effectiveness of Lymfactin®, an experimental adenoviral-based gene therapy vector that encodes human VEGF-C, for the treatment of breast cancer-related secondary LD (Hartiala et al, 2020b). This evidence concerns the gene VEGFC and breast carcinoma.